Neurocet Cliff's Notes Fail NAD Test For 'Stronger Than Morphine' Claim
This article was originally published in The Rose Sheet
Executive Summary
NAD says direct advertising claims for the Neurocet supplement rely on insufficient or ill-fitted research – including summaries – and marketer National Media Group should discontinue numerous statements challenged by the Council for Responsible Nutrition.
You may also be interested in...
Benefiber ‘Helps Maintain Regularity’ Claim Fails NAD Review; Decision Appealed
Novartis Health disagrees with the National Advertising Division decision that the Benefiber express claim “helps maintain regulatory” is not supported by research and will appeal the decision. NAD reviewed the claim made in a challenge by Metamucil fiber supplement marketer P&G.
Osteo Bi-Flex Claims Score Partial Victory In Appeal Of NAD Recommendation
The National Advertising Division's review board upheld most points of a recommendation that Rexall Sundown stop making certain claims for Osteo Bi-Flex dietary supplements, but said some claims can be used in ads and on packaging if "they are clearly qualified.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.